Israeli COVID-19 treatment appears successful with first two
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The first two patients who were treated with a new Israeli treatment for the novel COVID-19 after testing positive have shown significant improvement, with one of them even being removed from the Intensive care unit (ICU) within days of treatment.

Israeli biopharmaceutical RedHill Biopharma Ltd. administered their experimental drug, Opaganib, to which both patients have demonstrated significant improvement through clinical trial within mere days of treatment.

"Our hope is that the unique mechanism of action of Opaganib, with both anti-viral and anti-inflammatory activity, will help COVID-19 patients by reducing lung inflammation, and thus preventing the disease from progressing to a stage which requires mechanical ventilation. Importantly, Opaganib is targeting a critical host factor that the coronavirus is unlikely to evade via mutation in possible future outbreaks of the pandemic," said Medical Director at RedHill.

The two patients initially suffered from "moderate to severe acute respiratory symptoms related to SARS-CoV-2 infection, required supplemental oxygenation and were hypoxic despite being treated with maximum flow of oxygen with cannulas."
After the treatment, they both needed less supplemental oxygen as well as C-reactive protein, the latter of which is an "inflammatory biomarker correlated with lung lesions which could reflect disease severity."

An additional condition of the coronavirus is lymphocytopenia, meaning an abnormally low level of lymphocytes in the blood, which both of the patients started off with. A few days after the treatment, however, both patients showed significant improvement in that regard.

"We are very encouraged by the preliminary findings showing clinical improvement in the first COVID-19 patients treated with Opaganib, which further supports its safety and potential benefit to patients," said Medical Director at RedHill, Mark L. Levitt, MD, Ph.D.

Dr. J●●a J●●n and 55 others like this47 shares